scholarly journals Asthma care provider perspectives on exercise promotion in people with asthma: an examination of knowledge, practices, barriers, and facilitators

2021 ◽  
Vol 147 (2) ◽  
pp. AB41
Author(s):  
Sharmilee Nyenhuis ◽  
Karen Gregory ◽  
Basil Kahwash ◽  
Lisa Sharp
2017 ◽  
Vol 25 (7) ◽  
pp. 2297-2304 ◽  
Author(s):  
Michelle Nadler ◽  
Daryl Bainbridge ◽  
Jennifer Tomasone ◽  
Oren Cheifetz ◽  
Rosalyn A. Juergens ◽  
...  

2016 ◽  
Vol 34 (3_suppl) ◽  
pp. 155-155
Author(s):  
Cleo A. Samuel ◽  
Kea Turner ◽  
Heidi AS Donovan ◽  
G J. Van Londen

155 Background: Adjuvant endocrine therapy (AET)-related symptom management (SM) among breast cancer survivors (BCS) typically involves a multidisciplinary team of health care providers; yet few studies have examined provider perspectives on AET-related SM. The purpose of this study was to examine provider perspectives on the barriers and facilitators to AET-related SM among BCS and opportunities for improvement. Methods: We conducted 3 focus groups (FGs) with a multidisciplinary group of health care providers (n = [6] physician; n = [7] non-physician) experienced in caring for BCS undergoing AET. We utilized semi-structured discussion guides to elicit provider perspectives on AET-related SM and its barriers and facilitators as well as recommendations for improvement. All FGs were held at the University of Pittsburgh, audiotaped, and transcribed. We analyzed FG transcripts using qualitative software to identify key themes. Results: Providers described patient-, provider-, and system- level facilitators and barriers to AET-related SM. At the patient-level, facilitators included social support and provider communication about symptoms while cancer-related distress, misinformation and misinterpretation of online information were identified as barriers. Provider-level facilitators included strong relationships with other providers and ongoing communication with patients; however, lack of time, insufficient resources, and challenges distinguishing AET-related symptoms from other conditions were key provider-level barriers. Finally, at the system-level, electronic health records were described as both a facilitator and barrier to SM. Moreover, poor care coordination among different providers and lack of clear guidelines on which provider “owns” AET-related SM emerged as key system-level barriers. Conclusions: Findings suggest that efforts to improve AET-related SM should span multiple levels, in order to address patient-, provider-, and system-level barriers to SM. Recommendations include increased education for patients, greater access to clinical decision support tools for providers, and improved coordination of survivorship resources within hospitals.


Author(s):  
Rizawati Ramli ◽  
Ee Ming Khoo ◽  
Su May Liew ◽  
Nik Sherina Haidi Hanafi ◽  
Norita Hussein ◽  
...  

2011 ◽  
Vol 3 ◽  
pp. JCNSD.S4091 ◽  
Author(s):  
Heidi J. Wehring ◽  
Sheryl Thedford ◽  
Maju Koola ◽  
Deanna L. Kelly

Olanzapine long acting injection has joined risperidone and paliperidone as the second generation long acting antipsychotic injection options for treatment of patients with schizophrenia. Long acting injections are important alternatives to oral medications for patients who have difficulty adhering to daily or multiple daily medication administrations, yet may be underutilized or not well understood. Patient perceptions, adherence, and preferences are important issues for health care providers to address when discussing treatment options with their patients. Reviewed here are overall patient and health care provider attitudes and perceptions regarding long acting injections and the details of olanzapine long acting injectable, the newest agent, and how it will fit in the marketplace. In addition, efficacy, safety, dosing and use data regarding this newest long acting agent are reviewed and compared to other available long acting agents.


Sign in / Sign up

Export Citation Format

Share Document